Eiger BioPharmaceuticals (NASDAQ ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Trading Halts

Eiger BioPharmaceuticals (EIGR) Reports Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy October 17, 2018 4:08 PM Eiger BioPharmaceuticals (EIGR) Reports Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric HypoglycemiaOctober 16, 2018 4:06 PM Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH)October 16, 2018 4:05 PM